Found 706 clinical trials
Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor alpha Redirected T Cells for Recurrent High Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer
This is a Phase I study evaluating the safety and feasibility of intraperitoneal administered lentiviral transduced MOv19-BBz CAR-T cells in 4 cohorts with or without cyclophosphamide + fludarabine in a 3+3 dose escalation design. Up to 18 evaluable subjects will be treated.
UPCC 03419: A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkins Lymphoma
This trial is an open-label, multicenter, Phase 1b/2 trial investigating Hu5F9-G4 + rituximab (antibody combination) in R/R B-cell non-Hodgkins lymphoma (NHL) and Hu5F9-G4 + R-GemOx (chemotherapy combination) in indolent lymphoma and diffuse large B cell lymphoma (DLBCL)
UPCC 14419: A Phase 1 First in Human Study Evaluating the Safety Tolerability Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia
This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose escalation study of AMG 176 administered IV in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory AML.
UPCC 17418: A Phase 2b Open-Label Single Arm Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Standard Induction Therapy
The purpose of this research study is to measure the safety of BST-236 and how effective it is in treating patients with newly-diagnosed acute myeloid leukemia (AML) who are not eligible for standard induction chemotherapy.
UPCC 17419: A Phase 1b-2 Open-Label Study of JNJ-68284528 a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to investigate the use of a new, experimental drug called JNJ-68284528 in subjects with multiple myeloma.
Evaluation of Hyperfine Low Field Portable Point-of-Care Magnetic Resonance Imaging System in Patients with Hydrocephalus
Hydrocephalus is a medical condition in which an abnormal buildup of cerebrospinal fluid (CSF) causes the fluid-filled spaces of the brain, the ventricles, to become enlarged. Enlarged ventricles and increased intracranial pressure can cause headaches, dizziness, blurred vision, cognitive impairment, gait disturbances and in severe cases even brain herniation or …
UPCC 06518: A Phase 2 Precision Oncology Study of Biomarker-Directed Pembrolizumab-Based Combination Therapy for Advanced Non-Small Cell Lung Cancer
To evaluate the clinical activity (as assessed by objective response rate [ORR]) pembrolizumab (MK-3475) in combination with MK-4280 or lenvatinib in study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic treatment for their advanced disease.
UPCC 19418: A Phase 1/2a Dose-Finding Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma
Multicenter, open-label study of PT-112 in patients with relapsed/refractory MM. The study will be conducted in two parts. The first part of the study involves dose-escalation, in which successive cohorts of patients will receive escalating doses of PT-112 until the maximum tolerated dose (MTD) is reached. The second part of …
UPCC 13418: A Multicenter Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia
The purposes of this study are to see if the study drugs, venetoclax and gilteritinib can be safely and effectively combined for the treatment of patients with acute myeloid leukemia (AML) that has returned after prior treatment, or has failed to respond to prior treatment and identify potential biomarkers.
UPCC 02619: Adjuvant Nivolumab Or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab
Subjects with Stage III resectable melanoma will receive adjuvant therapy, nivolumab or ipilimumab plus nivolumab, based on whether a pathologic complete response (CR) or near CR (less than 10% viable tumor cells) is achieved with one dose of nivolumab in the neoadjuvant setting followed by surgery.
